A Phase 1b, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HJB647 Following Single Ascending Dose and Up-titration Multiple Dose Administration in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension (CHJB647A11101)

未提供0 个研究点目标入组 74 人开始时间: 待定

适应症

试验速览

暂无简介。

•Japanese healthy participants with elevated blood pressure (Part 1) and patients with mild-to-moderate hypertension (Part 2)
•Age: 18 to 55 years (Part 1) and 18 to 60 years (Part 2)
•Body weight:
•Male: >= 50.0 kg
•Female: >= 45.0 kg
•Body Mass Index (BMI): 18.0 to 30.0 kg/m2
•Axillary body temperature: 35.0-37.5 celsius degree
•Heart rate: 50-90 bpm
•Blood pressure criteria are as follows:
•Part 1: Healthy Participants with Elevated Blood Pressure Screening: Systolic Blood Pressure (SBP): 120 =< SBP =< 139 mmHg; Diastolic Blood Pressure (DBP): 60 =< DBP =< 94 mmHg Baseline (Day -1): SBP: 120 =< SBP =< 179 mmHg; DBP: 60 =< DBP =< 109 mmHg
•Part 2: Patients with Hypertension Screening and Baseline (Day -1): SBP: 140 =< SBP =< 179 mmHg; DBP: 60 =< DBP =< 109 mmHg

•Significant illness, including infectious diseases that have not resolved within 30 days prior to baseline
•History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as:
•Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker.
•History of familial long QT syndrome or known family history of Torsades de Pointes
•Resting QT interval corrected by Fridericia's formula (QTcF) >= 450 msec (male) or >= 460 msec (female) at screening
•At screening, hypokalemia or hypomagnesemia defined as potassium or magnesium values below the LLN on repeat measurement, or laboratory abnormalities indicating hypothyroidism, as determined at the discretion of the investigator
•HbA1c >= 7.0% or LDL cholesterol >= 180 mg/dL or triglycerides >= 250 mg/dL
•Use of any prescription drugs or herbal supplements within 4 weeks prior to initial dosing, and/or OTC medication or dietary supplements (vitamins included) within 2 weeks prior to initial dosing
•Women of childbearing potential

发起方

未提供